Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.

Annals of hematology - 1 Jul 2024

Cai Xiaoya, Liu Ying, Li Huimin, Que Yimei, Xiao Min, Wang Ying, Wang Xiong, Li Dengju

Abstract excerpt

Acute myeloid leukemia (AML) patients with DNA methyltransferase 3A (DNMT3A) mutation display poor prognosis, and targeted therapy is not available currently. Our previous study identified increased expression of Exportin1 (XPO1) in DNMT3AR882H AML patients. Therefore, we further investigated the therapeutic effect of XPO1 inhibition on DNMT3AR882H AML. Three types of DNMT3AR882H AML cell lines were generated,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA (Cytosine-5-)-Methyltransferases
Share to DNA Methyltransferase 3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exportin 1 Protein

Share to Glutathione

Share to Hydrazines

Share to Karyopherins

Share to Receptors, Cytoplasmic and Nuclear

Share to Triazoles

Source

Identifiers

PMID: 38519605
DOI: 10.1007/s00277-024-05706-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.PMID 38519605Read ↗

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaSemantic proximity Read ↗

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.Semantic proximity Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

Targeting SMC3 deacetylation synergizes with XPO1 inhibition to reprogram the epigenetic landscape and suppress NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in <i>NPM1</i> -mutated AMLSemantic proximity Read ↗

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AMLSemantic proximity Read ↗

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1Semantic proximity Read ↗

Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.Semantic proximity Read ↗

A three gene signature predicts response to selinexor in multiple myelomaSemantic proximity Read ↗

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agentsSemantic proximity Read ↗

Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication GenesSemantic proximity Read ↗

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.